Prosthetic valve endocarditis after transcatheter aortic valve replacement in low-risk patients.
aortic valve disease
endocarditis
percutaneous intervention
stroke
transcatheter valve implantation
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
06
08
2021
received:
18
06
2021
accepted:
27
08
2021
pubmed:
11
9
2021
medline:
8
4
2022
entrez:
10
9
2021
Statut:
ppublish
Résumé
We sought to report details of the incidence, organisms, clinical course, and outcomes of prosthetic valve endocarditis (PVE) after transcatheter aortic valve replacement (TAVR) in low-risk patients. PVE remains a rare but devastating complication of aortic valve replacement. Data regarding PVE after TAVR in low-risk patients are lacking. We performed a detailed review of all patients in the low-risk TAVR trials who underwent TAVR from 2016 to 2020 and were adjudicated to have definitive PVE by the independent Clinical Events Committee. We analyzed 396 low-risk patients who underwent TAVR (including 72 with bicuspid valves). PVE occurred in 11 patients at a median 379 days (210, 528) from TAVR. The incidence within the first 30 days was 0%; days 31-365, 1.5%; and after day 365, 2.8%. The most common organism identified was Streptococcus (n = 4/11). Early PVE (≤ 365 days) occurred in five patients, of whom three demonstrated evidence of embolic stroke and two underwent surgical aortic valve re-intervention. Late PVE (> 365 days) occurred in six patients, of whom thee demonstrated evidence of embolic stroke and only one underwent surgical aortic valve re-intervention. Of the six patients with evidence of embolic stroke, two died, two were discharged to rehabilitation, and two were discharged home with home care. PVE was infrequent following TAVR in low-risk patients but was associated with substantial morbidity and mortality. Embolic stroke complicated the majority of PVE cases, contributing to worse outcomes in these patients. Efforts must be undertaken to minimize PVE in TAVR.
Sections du résumé
OBJECTIVES
We sought to report details of the incidence, organisms, clinical course, and outcomes of prosthetic valve endocarditis (PVE) after transcatheter aortic valve replacement (TAVR) in low-risk patients.
BACKGROUND
PVE remains a rare but devastating complication of aortic valve replacement. Data regarding PVE after TAVR in low-risk patients are lacking.
METHODS
We performed a detailed review of all patients in the low-risk TAVR trials who underwent TAVR from 2016 to 2020 and were adjudicated to have definitive PVE by the independent Clinical Events Committee.
RESULTS
We analyzed 396 low-risk patients who underwent TAVR (including 72 with bicuspid valves). PVE occurred in 11 patients at a median 379 days (210, 528) from TAVR. The incidence within the first 30 days was 0%; days 31-365, 1.5%; and after day 365, 2.8%. The most common organism identified was Streptococcus (n = 4/11). Early PVE (≤ 365 days) occurred in five patients, of whom three demonstrated evidence of embolic stroke and two underwent surgical aortic valve re-intervention. Late PVE (> 365 days) occurred in six patients, of whom thee demonstrated evidence of embolic stroke and only one underwent surgical aortic valve re-intervention. Of the six patients with evidence of embolic stroke, two died, two were discharged to rehabilitation, and two were discharged home with home care.
CONCLUSIONS
PVE was infrequent following TAVR in low-risk patients but was associated with substantial morbidity and mortality. Embolic stroke complicated the majority of PVE cases, contributing to worse outcomes in these patients. Efforts must be undertaken to minimize PVE in TAVR.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
896-903Subventions
Organisme : MedStar Health Research Institute
Organisme : Medtronic
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Bjursten H, Rasmussen M, Nozohoor S, et al. Infective endocarditis after transcatheter aortic valve implantation: a nationwide study. Eur Heart J. 2019;40:3263-3269.
Summers MR, Leon MB, Smith CR, et al. Prosthetic valve endocarditis after TAVR and SAVR: insights from the PARTNER trials. Circulation. 2019;140:1984-1994.
Stortecky S, Heg D, Tueller D, et al. Infective endocarditis after transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;75:3020-3030.
Mentias A, Girotra S, Desai MY, et al. Incidence, predictors, and outcomes of endocarditis after transcatheter aortic valve replacement in the United States. JACC Cardiovasc Interv. 2020;13:1973-1982.
Regueiro A, Linke A, Latib A, et al. Infective endocarditis following Transcatheter aortic valve replacement: comparison of balloon- versus self-expandable valves. Circ Cardiovasc Interv. 2019;12:e007938.
Regueiro A, Linke A, Latib A, et al. Association between Transcatheter aortic valve replacement and subsequent infective endocarditis and in-hospital death. JAMA. 2016;316:1083-1092.
Ullah W, Khan MS, Gowda SN, Alraies MC, Fischman DL. Prosthetic valve endocarditis in patients undergoing TAVR compared to SAVR: a systematic review and meta-analysis. Cardiovasc Revasc Med. 2020;21:1567-1572.
FDA expands indication for several transcatheter heart valves to patients at low risk for death or major complications associated with open-heart surgery. Accessed January 21, 2021. https://www.fda.gov/news-events/press-announcements/fda-expands-indication-several-transcatheter-heart-valves-patients-low-risk-death-or-major
Feasibility of Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic, Severe Aortic Stenosis. Accessed January 21, 2021. https://clinicaltrials.gov/ct2/show/NCT02628899. 2021.
Strategies to Prevent Transcatheter Heart Valve Dysfunction in Low Risk Transcatheter Aortic Valve Replacement (NCT03557242). Accessed January 21, 2021. https://clinicaltrials.gov/ct2/show/NCT03557242. 2021.
Kappetein AP, Head SJ, Genereux P, et al. Valve academic research consortium (VARC)-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg. 2012;42:S45-S60.
Shahian DM, O'Brien SM, Filardo G, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1- -coronary artery bypass grafting surgery. Ann Thorac Surg. 2009;88:S2-S22.
Habib G, Lancellotti P, Antunes MJ, et al. Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36:3075-3128.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706-1715.
Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187-2198.
Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609-1620.
Dahl A, Iversen K, Tonder N, et al. Prevalence of infective endocarditis in enterococcus faecalis bacteremia. J Am Coll Cardiol. 2019;74:193-201.
Roder BL, Wandall DA, Frimodt-Moller N, Espersen F, Skinhoj P, Rosdahl VT. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch Intern Med. 1999;159:462-469.
Rajani R, Klein JL. Infective endocarditis: a contemporary update. Clin Med (Lond). 2020;20:31-35.
Figulla HR, Franz M, Lauten A. The history of Transcatheter aortic valve implantation (TAVI)-a personal view over 25Years of development. Cardiovasc Revasc Med. 2020;21:398-403.
Waksman R, Rogers T, Torguson R, et al. Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis. J Am Coll Cardiol. 2018;72:2095-2105.
Waksman R, Craig PE, Torguson R, et al. Transcatheter aortic valve replacement in low-risk patients with symptomatic severe bicuspid aortic valve stenosis. JACC Cardiovasc Interv. 2020;13:1019-1027.
Rogers T, Shults C, Torguson R, et al. Randomized trial of aspirin versus warfarin after Transcatheter aortic valve replacement in low-risk patients. Circ Cardiovasc Interv. 2021;14:e009983.
Williams M. The PARTNER 3 Trial Bicuspid Registry for SAPIEN 3 TAVR in Low-Risk Patients. Accessed January 21, 2021. https://www.tctconnect.com/cme-program-transcatheter-aortic-valve-replacements-for-bicuspid-aortic-valves-sponsored-by-crf-and-supported-through-an-unrestricted-educational-grant-by-edwards-lifesciences/
Forrest JK, Ramlawi B, Deeb GM, et al. Transcatheter aortic valve replacement in low-risk patients with bicuspid aortic valve stenosis. JAMA Cardiol. 2021;6:50-57.
Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321-1331.
Adams DH, Popma JJ, Reardon MJ, et al. For the U.S. CoreValve clinical investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790-1798.